Cover Image

Tolerability of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch: a multicenter, retrospective study

Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well, their physicians may switch to a different combination; howeve...

Full description

Saved in:
Bibliographic Details
Main Authors: Salzmann, Martin (Author) , Wald, Alexander (Author) , Stege, Henner (Author) , Loquai, Carmen (Author) , Zimmer, Lisa (Author) , Hayani, Kinan M. (Author) , Heinzerling, Lucie (Author) , Gutzmer, Ralf (Author) , Enk, Alexander (Author) , Hassel, Jessica C. (Author)
Format: Article (Journal)
Language:English
Published: 23 February 2023
In: Cancers
Year: 2023, Volume: 15, Issue: 5, Pages: 1-12
ISSN:2072-6694
DOI:10.3390/cancers15051426
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers15051426
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/15/5/1426
Get full text
Author Notes:Martin Salzmann, Alexander Wald, Henner Stege, Carmen Loquai, Lisa Zimmer, Kinan M. Hayani, Lucie Heinzerling, Ralf Gutzmer, Alexander H. Enk and Jessica C. Hassel
Description
Summary:Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well, their physicians may switch to a different combination; however, it has not been evaluated whether the second combination is actually tolerated better. ...
Item Description:Gesehen am 07.12.2023
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers15051426

Similar Items